Your browser doesn't support javascript.
loading
Hypertrophic Cardiomyopathy: New Concepts and Therapies.
Maron, Barry J; Rowin, Ethan J; Maron, Martin S.
Afiliação
  • Maron BJ; Division of Cardiology, Hypertrophic Cardiomyopathy Institute, Tufts Medical Center, Boston, Massachusetts 02111; email: Barrymaron1@gmail.com.
  • Rowin EJ; Division of Cardiology, Hypertrophic Cardiomyopathy Institute, Tufts Medical Center, Boston, Massachusetts 02111; email: Barrymaron1@gmail.com.
  • Maron MS; Division of Cardiology, Hypertrophic Cardiomyopathy Institute, Tufts Medical Center, Boston, Massachusetts 02111; email: Barrymaron1@gmail.com.
Annu Rev Med ; 73: 363-375, 2022 01 27.
Article em En | MEDLINE | ID: mdl-35084989
ABSTRACT
Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited myocardial disorder, transformed over the last several years into a treatable condition with the emergence of effective management options that alter natural history at all ages. Now available are a matured risk stratification algorithm selecting patients for prophylactic implantable defibrillators that prevent arrhythmic sudden death; low-risk, high-benefit surgical myectomy to reverse progressive heart failure symptoms due to left ventricular outflow obstruction; anticoagulation prophylaxis to prevent atrial fibrillation-mediated embolic stroke; and heart transplant for refractory end-stage disease in the absence of obstruction. Those strategies have resulted in reduction of HCM-related morbidity and reduction of mortality to 0.5% per year.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Cardiomiopatia Hipertrófica / Desfibriladores Implantáveis Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Cardiomiopatia Hipertrófica / Desfibriladores Implantáveis Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article